Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,525 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline (Placebo Control) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

NCT03173625
View directory record Official record
Conditions
Healthy Subjects
Interventions
AC-076 for s.c. administration, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 14, 2026, 1:15 PM EDT
Terminated Phase 2 Interventional

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

NCT03911076
View directory record Official record
Conditions
ASC-US, ASC-H, LSIL
Interventions
PVX-2, Placebo
Biological · Other
Lead sponsor
PapiVax Biotech, Inc.
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT05274750
View directory record Official record
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?

NCT01813058
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section

NCT00432991
View directory record Official record
Conditions
Nausea, Vomiting, Cesarean Section
Interventions
Ephedrine [Synonyms: Ephedra, Ephedrinum], Saline Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 14, 2026, 1:15 PM EDT
Terminated Phase 3 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

NCT04095858
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
Interventions
Efprezimod alfa, Placebo, Methotrexate, Tacrolimus
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 14, 2026, 1:15 PM EDT
Recruiting Phase 3 Interventional

Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment

NCT06247085
View directory record Official record
Conditions
Homocystinuria
Interventions
Pegtibatinase, Placebo
Drug · Other
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Higher Dose Intradermal H5 Vaccine

NCT00439335
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

NCT03293498
View directory record Official record
Conditions
Influenza
Interventions
NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 14, 2026, 1:15 PM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 3 Interventional Results available

Bunionectomy Study for Postoperative Analgesia (EPOCH 1)

NCT03295721
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Saline Placebo, Bupivacaine HCl, Luer-lock applicator, Vial access device
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Early Phase 1 Interventional Results available

Adrenergic System in Islet Transplantation

NCT03079921
View directory record Official record
Conditions
Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
Interventions
Phentolamine, Propranolol, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers

NCT04808414
View directory record Official record
Conditions
Bacterial Infections
Interventions
QPX9003 for IV Infusion, Placebo for IV infusion
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

NCT05288504
View directory record Official record
Conditions
Non-Eosinophilic Asthma
Interventions
AVTX-002, Placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Sacramento, California • Walnut Creek, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults

NCT02337855
View directory record Official record
Conditions
Schistosomiasis
Interventions
Placebo, Sm-TSP-2/Alhydrogel, Sm-TSP-2/Alhydrogel/GLA-AF
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)

NCT00681655
View directory record Official record
Conditions
Alcoholism
Interventions
Alcohol, Placebo
Other
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 27 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B

NCT00764634
View directory record Official record
Conditions
Botulism Vaccine
Interventions
Placebo (USP sterile saline for injection), rBV A/B-40 vaccine
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
Miami, Florida • Pembroke Pines, Florida • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2011 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury

NCT01322009
View directory record Official record
Conditions
Pediatric Traumatic Brain Injury
Interventions
Probenecid and N-acetyl cysteine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
2 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Tranexamic Acid in Reverse Total Shoulder Arthroplasty

NCT02043132
View directory record Official record
Conditions
Shoulder Joint Disease, Complications; Arthroplasty, Intraoperative Complications, Blood Loss, Surgical
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 14, 2026, 1:15 PM EDT
Recruiting Phase 3 Interventional

Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression

NCT05058287
View directory record Official record
Conditions
Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative, Pain, Back
Interventions
Depo-Medrol 40Mg/Ml Suspension for Injection, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 4 Interventional Results available

Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)

NCT01356147
View directory record Official record
Conditions
Pulmonary Infections
Interventions
Dornase alfa, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
7 Days to 4 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 14, 2026, 1:15 PM EDT
Recruiting Phase 3 Interventional

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

NCT06880770
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Plozasiran, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Los Angeles, California • Santa Clarita, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

NCT02966028
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease, ESRD, Coronary Artery Calcification
Interventions
SNF472, Placebo
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
46
States / cities
Bakersfield, California • Chula Vista, California • Escondido, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 14, 2026, 1:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating

NCT01671800
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Type B, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 14, 2026, 1:15 PM EDT